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Abstract: It is well established that the intracellular accumulation of beta-amyloid is associated with Alzheimer’s disease and
that this accumulation is toxic to neurons. The precise mechanism by which this toxicity occurs is not well understood, however,
identifying the causes of this toxicity is an essential step in developing treatments for Alzheimer’s disease. One intracellular
location where the accumulation of beta-amyloid can have a major effect is within mitochondria has identified mitochondrial
proteins that act as binding sites for beta-amyloid and when binding occurs a toxic response results. For one of these identified
sites, an enzyme known as ‘ABAD’, we have identified the changes in gene expression in the brain cortex following beta-
amyloid accumulation within mitochondria. Specifically, we have identified two proteins that are upregulated in the brains of
transgenic animal models for Alzheimer’s disease but also human sufferers. The increased expression of these proteins
demonstrates the complex and counter-acting pathways that are activated in Alzheimer’s disease. Previous studies have identified
the approximate contact sites between ABAD and beta-amyloid, and based on these observations we have shown that using a
modified peptide approach, it is possible to reverse the expression of these two proteins in living transgenic animals and also
recover both mitochondrial and behavioural deficits. This indicates that the ABAD-beta-amyloid interaction is potentially an
interesting target for therapeutic intervention. To explore this further we used a fluorescing substrate mimic to measure the
activity of ABAD within living cells, and in addition we have identified chemical fragments that bind to ABAD, by using a
thermal shift assay.
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linked-immunosorbent assay; Ep-1, endophilin-1; ER, endoplasmic reticulum; ERAB, ER associated amyloid binding protein;
JNK, c-Jun-N-terminal kinase; mAPP, mutant amyloid precursor protein; the mitochondrial permeability transition pore mPTP;
PiC, mitochondrial phosphate carrier; Prx-2, peroxiredoxin-2; ROS, reactive oxygen species; SPR, surface Plasmon resonance;
TOM, translocase of outer mitochondrial membrane; VDAC, voltage-dependent anion channel
Introduction
A link between mitochondrial dysfunction and neurodegenerative conditions
such as Alzheimer’s disease (AD), has long been suggested. Observations in dementia
patients of altered cerebral blood flow and bioenergetic deficits in dementia patients
using positron electron tomography (1-2) initiated research into the function of
mitochondria in neurodegeneration, as they are central to cellular energy metabolism.
Evidence has since accumulated for the pivotal role of metabolic pathways and free-
radical turnover in mitochondria during both normal aging and neurodegenerative
diseases (3-4). For example, Parker and colleagues detected reduced cytochrome C
oxidase activity in the platelets (5) and the brains of AD patients (6) while Sayre et al.
found increased levels of 4-hydroxynonenal (4-HNE), a product of lipid peroxidation,
in AD brain tissue compared to controls (7). Due to the proximity of mitochondrial
DNA to reactive oxygen species (ROS), which are naturally produced in the electron
transport chain, this DNA is thought to accumulate mutations over time, which can
lead to increasing mitochondrial dysfunction and increased production of ROS with
age (8-10). Key mitochondrial enzymes, that are affected by AD include cytochrome
C oxidase (5, 11), the pyruvate dehydrogenase complex, α-ketoglutarate 
dehydrogenase and the isocitrate-dehydrogenase (12-13).
Lustbader et al. used immunoelectron microscopy to show that mitochondrial
β-amyloid (Aβ) (both the 1-40, and 1-42 forms) localises inside the mitochondria of 
both mutant anyloid precursor protein (mAPP) over-expressing transgenic animals
(Tg mAPP) and, significantly, the human AD brain (14). A further study showed that
Aβ accumulation in the mitochondria from Tg mAPP mice and the cerebral cortex of 
human AD brains is significantly higher than in non-transgenic mice and non-AD
brains (15). More recent studies, indicate that mitochondrial dysfunction and the
accumulation of mitochondrial A (and ABAD: see below) can be observed in the
early disease stages of AD in other commonly used transgenic animal strains,
including the popular triple transgenic mouse model (human APPSWE, TauP301L, and
PS1M146V;(16)).
The origin of this mitochondrial Aβ is still under debate and there is 
experimental evidence for both the local production (for example the presence of the
-secretase complex within mitochondria) and/or the import of Aβ from the cytosol 
via the translocase of outer mitochondrial membrane (TOM) (17-19). In addition to
the ongoing efforts to identify how Aβ occurs within mitochondria, the other key 
question regards the action of Aβ once it is located within mitochondria. The addition 
of Aβ to cell cultures induces dysfunction of mitochondrial respiration, ATP depletion 
and production of ROS (20-21) and exposure of isolated mitochondria to Aβ reduces 
complex IV activity (22) and induces the formation of the permeability transition
pore, which is linked to cell death (23). In addition to these organelle-level changes,
within the last decade attention has increasingly focused on two mitochondrial
proteins, amyloid binding alcohol dehydrogenase (ABAD) and Cyclophilin D
(CypD), both of which appear able to mediate the toxicity of the Apeptide. Binding
of both proteins to Aβ (both the 1-40 and 1-42 forms) has been demonstrated at nM 
Aβ concentrations, and Aβ accumulation within cells is known to result in an increase 
in expression of both of these proteins (23-25).
Cyclophilin D
CypD, a peptidylprolyl isomerise F, is found in the mitochondrial matrix and
translocates to the inner mitochondrial membrane during times of oxidative stress
where it is thought to play a role in the opening of the mitochondrial permeability
transition pore (mPTP) (26). CypD is considered to be a part of the mPTP as it
associates with adenine nucleotide translocase (ANT) and possibly other factors, like
the voltage dependent anion channel (VDAC) and the mitochondrial phosphate carrier
(PiC) to contribute to the opening of the pore (27). Using a variety of methods such as
immunoprecipitation, co-localisation and surface plasmon resonance (SPR) assays it
was shown that CypD can bind to Aβ at nM concentrations of Aβ, However, no direct 
contact sites have yet been identified (23). Du et al. (23) also reported that under Aβ 
rich conditions in the aging brain, CypD expression levels are increased and coincide
with increased levels of ROS production. Further studies using Tg mAPP mice
deficient in the gene encoding CypD revealed that the interaction of CypD with Aβ 
can result in cellular stress and cell death (23, 25). Notably, neurons derived from
CypD deficient animals are resistant to Aβ-induced opening of the mPTP, and are 
thus protected against Aβ- and oxidative stress-induced cell death. These animals also 
exhibited significantly improved learning and memory function when compared to
transgenic mAPP mice with normal expression of CypD (25).
Amyloid binding alcohol dehydrogenase (ABAD)
ABAD is the most characterised intracellular Aβ-binding protein and was first 
identified in 1997 using a yeast two-hybrid screen (24). It was originally identified
within the endoplasmic reticulum (ER) and termed ERAB (ER associated amyloid
binding protein) (24), however, later studies confirmed its presence inside
mitochondria (28). The action of this enzyme is primarily to catalyse the reduction of
aldehydes and ketones or the reverse reaction of oxidation from alcohols for energy
production. As described in more detail by Muirhead et al. (2010) (29) ABAD acts on
a variety of substrates, indicating the variety of functions it can have within the cell.
This variety of potential substrates correlates with the finding that ABAD appears to
act as a molecular switch. In the presence of low levels of A ABAD can have
neuroprotective effects, and its increased expression is protective in animal models for
Parkinsonism (30) and metabolic stress (31); however, as A levels rise, it appears
that ABAD loses its ability to protect and enhances A toxicity (32). X-ray
crystallography studies of both human and rat ABAD have provided a clear
representation of the catalytic core of ABAD and enabled the identification of key
residues involved in substrate binding and the interacftion with Aβ (33). However the
precise residues involved in the Aβ-ABAD interaction could not be indentified by 
crystallography as loop D, the region that is thought to bind Aβ, was disordered in the 
structure (14). The interaction with Aβ not only inhibits ABAD’s enzyme function 
(though notably only at M concentrations) (28, 34), but importantly also causes
severe mitochondrial dysfunction and cellular toxicity (14, 32), which cannot be
attributed to a loss of enzyme function alone. Proteomics studies on mice over-
expressing ABAD and mAPP revealed that in the living brain the ABAD-Aβ 
interaction also affects the expression of proteins. Those proteins specifically
identified were Endophilin-1 (Ep-1) (35) and Peroxiredoxin-2 (Prdx-2) (36), both of
which were found to be more abundant in human AD brains compared to controls
(35-36). To date, the link between these two proteins and mitochondrial dysfunction
remains unclear. However, evidence exists that increased levels of Ep-1 can cause the
activation of c-Jun-N-terminal kinase (JNK) (35, 37). JNK is a stress kinase which
has been linked to Aβ  production in neuronal cells (38-39) and the action of which is
associated with the early stages of AD (40). Conversely, Prdx-2 is an anti-oxidant
protein and an increase in its expression can protect against A-induced toxicity (36).
Thus the increased expression of these two proteins typifies the competing pathways
that are activated in the AD diseased brain.
Another important metabolic function located in mitochondria is Ca2+
homeostasis. Evidence for disturbed Ca2+ homeostasis (41) and alterations in Ca2+
regulated proteins, especially the neuronal proteinase calpain and its targets, have
been detected in human AD brains, in human cortical neuron cultures in vitro (42-43)
and transgenic mice (44). Interestingly, a link between the calpain-regulated cyclin-
dependent kinase 5 (Cdk 5) and Prdx-2 inactivation by phosphorylation has been
discovered in a model for Parkinson’s disease (45). In addition, Cdk 5 had been
earlier identified as a candidate kinase for mediating neuronal toxicity in AD (46-48).
The relevance of this pathway for Prdx-2 function in AD has not been investigated so
far. Our own studies indicate that the phosphorylation of Thr89 in Prdx-2 can
regulated the observed protection against Aβ-induced toxicity (Borger, unpublished 
observations). More recently a novel Ca2+ binding protein, EFHD 2 (swiprosin 1) has
also been linked to one of the hallmarks of AD (49). EFHD 2 is more associated with
hyperphosphorylated tau protein in a mouse tauopathy model and in human AD
brains, than in control tissues (49). Additionally, it was reported that the protein levels
of EFHD 2 were increased in AD cases compared to controls (49) and our own
studies suggest that this is also the case in the Tg mAPP mouse model, which does not
develop tauopathy (Borger, unpublished results). The function of EFHD 2 in neuronal
cells is still unknown, but its association with two of AD hallmarks points towards a
potential importance in AD pathology.
Taken together, research on human dementia patients and studies using animal
as well as in vitro models for AD have shown that all the key functions of
mitochondria are affected in AD. A detrimental link between impaired brain energy
metabolism, ROS production and disturbed Ca2+ homeostasis has also been
established for other neuropathological conditions such as delirium, ischemia and
hypoglycaemia. Consequently, Blass and colleagues have proposed a role for a
downward “mitochondrial spiral” in the development of neurodegenerative diseases,
in particular for AD (50-52).
Therapeutic targets and development of assays
The proposed binding site of Aβ on ABAD, “loop D”, was identified through a 
range of complimentary techniques including X-ray crystallography and mutagenesis
studies (14). It has been shown that a synthetic peptide consisting of residues 92-120
which form this loop can be used as a “decoy peptide” (DP), which competes with
ABAD as a binding partner for A. Using SPR, it was shown that this “decoy
peptide” was able to prevent the binding of Aβ to ABAD (14). The same region of
ABAD, identified independently through an antisense peptide approach, was found to
bind biotinylated Aβ with a Kd of 107 nM using ELISA (53). Cellular studies of the
DP effects, using a Tat-DP fusion peptide to allow the peptide to cross the cell
membrane, found that application of the peptide was protecting neurons (from wild
type, Tg-ABAD and Tg-ABAD/mAPP mice) against Aβ-induced toxicity (14).
Similarly, introduction of DP-TRX (TRX = thioredoxin 1, an enzyme introduced here
in order to stabilise the peptide) into cell cultures using a lentiviral approach revealed
that DP-TRX-transfected cells showed decreased apoptosis, decreased LDH release
and increased cell viability after treatment with Aβ compared to controls (54).
Compelling evidence for the effectiveness of the peptide came from in vivo studies in
transgenic animals, where a fusion peptide consisting of amino acids 93-116 of loop
D with a Tat sequence and a mitochondrial targetings sequence (Tat-mito-DP(93-
116)) was found to alter levels of the AD biomarker proteins Prdx II and Ep I (35-36).
Intraperitoneal injection of Tat-mito-DP(93-116) into Tg mAPP mice resulted in a
reduction of Prdx II levels in these mice to levels comparable with non-transgenic
mice (36). Similarly, Ep I levels were elevated in double transgenic ABAD/ mAPP
mice and were found to return to basal levels when the mice were treated with Tat-
mito-DP(93-116) (35). In addition, behavioural studies revealed that treatment with
the DP improved short-term memory performance in transgenic AD mouse models.
Recently Yao et al. demonstrated, that both double transgenic mAPP/Tat-mito-DP(91-
119) mice as well as mAPP mice systemically treated with the decoy peptide showed
significant improvement in the radial-arm water maze test for short-term memory
performance compared with untreated mAPP mice (55).
In order to develop therapeutic compounds that target the Aβ-ABAD 
interaction, a robust method for monitoring the activity of the desired drug target is
required. The use of purified ABAD protein to measure enzyme activity in vitro is
well documented (29). Utilising the absorption of NADH at 340 nm, the rate of
reduction of substrate can be measured by spectroscopy. Recently we and our
collaborators have developed a cell-based assay that enables the study of ABAD
activity in intact living cells. The assay uses a fluorescent ABAD substrate mimic,
cyclohexenyl amine naphthalene alcohol (CHANA), which was based on the
endogenous ABAD substrate oestradiol. CHANA is a non-fluorescent substrate under
the assay conditions, while the reaction product cyclohexenyl amine naphthalene
ketone CHANK fluoresces in non-aqueous environments, e.g. in cell membranes (56).
Due to these different photochemical properties, selective detection of the
accumulation of CHANK is possible. Thus the conversion of CHANA to CHANK,
and hence ABAD activity, can be monitored by fluorescence microscopy. This novel
approach has recently been improved by synthesis of the individual stereoisomers of
CHANA. (–)-CHANA was found to be selectively metabolised by ABAD, while (+)-
CHANA showed a much higher level of background oxidation by other cellular
dehydrogenases (57). Thus, using (–)-CHANA, we have laid the foundations for a
cell-based assay monitoring ABAD activity. Using (–)-CHANA metabolism was seen
to be substantially diminished in cells treated with a known ABAD inhibitor,
AG18051 (33). Importantly, it was also demonstrated that Aβ can inhibit ABAD 
activity in living cells. Upon addition of 22 μM Aβ(1-42), HEK293 cells were shown 
to exhibit a significant decrease in (–)-CHANA metabolism of around 20%. It is
hoped that further development of this system will provide a robust cell-based assay
for use in identifying potential modulators of ABAD function (57).
The Future
AD is a complex disease, and likewise it becomes more and more apparent
that the toxicity of the Aβ peptide is also a complex process. Indeed whilst many 
approaches to explain AD pathology have centred on extracellular A, there has been
less focus on the involvement of intracellular species of Aβ. Our studies with our 
collaborators have focussed on these events (summarised in Figure 1). They suggest
that the one drug and one target approach for the treatment of AD are unlikely to be
an effective strategy for the treatment of AD. Consequently, the treatment of this
disease will likely require a three armed approach, targeting for example: 1) The
formation/ clearance of Aβ and hyperphosphorylated tau; 2) The support and 
stabilisation of the remaining neuronal networks and 3) Protection of potential
sensitive intracellular targets. The integrity and function of mitochondria is one such
sensitive intracellular target, and though ABAD and CypD are not classical drug
targets they are important players in the sequence of events resulting in mitochondrial
dysfunction. Therefore, future treatment approaches to the treatment of AD will
greatly benefit from understanding their involvement in AD.
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Figure 1: Consequences of mitochondrial Aβ 
APP can be transported to mitochondria, where it interacts with TOM and TIM
(transolcase of the inner membrane), disturbing mitochondrial protein import (1). Aβ 
can be imported into mitochondria via TIM and TOM and is found associated with the
inner mitochondrial membrane, disrupting mitochondrial respiration and leading to
excess production of ROS (2). Aβ has been found to interact with ABAD in the 
mitochondrial matrix, inhibiting the enzyme (3). The Aβ-ABAD interaction also leads 
to an up-regulation of AD biomarkers Ep-1 (4) and Prdx-2 (5). At the inner
mitochondrial membrane, Aβ can with CypD, which is involved in the formation of 
the mPTP and Ca2+-relase from mitochondria (6). Aβ can be found in the cytosol, 
disturbing cell signalling, protein degradation and causing ROS production, which
leads to an increase in cytosolic Ca2+ (7). Ca2+ mediated Cdk5 activation has been
found to inhibit the Prdx II antioxidant function.
